• Publications
  • Influence
Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials.
Testosterone replacement in older men was associated with a significantly higher risk of detection of prostate events and of hematocrit >50% than was placebo; he matocrit increase was the most frequent adverse event associated with testosterone replacement. Expand
Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone.
T therapy in older men with low serum testosterone levels increases vertebral and hip BMD over 36 months, both when administered alone and when combined with F, and suggests that dihydrotestosterone is not essential for the beneficial effects of T on BMD in men. Expand
Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.
It is demonstrated that T therapy in older men with low serum T improves physical performance and strength over 36 months, when administered alone or when combined with F, and suggested that high serum levels of dihydrotestosterone are not essential for these beneficial effects of T in men. Expand
Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone.
The results indicate that T replacement, whether given alone or in combination with finasteride, for 36 months in healthy older men without cognitive impairment at baseline has no clinically significant effect on tests of cognitive function. Expand
Experience with testosterone replacement in the elderly.
Treatment effects that make a relatively small difference in younger, more robust individuals may have a greater effect on the elderly, whose improvement in functioning and level of activity may be more dramatic. Expand
Issues in testosterone replacement in older men.
Male hormone replacement therapy including "andropause".
  • J. Tenover
  • Medicine
  • Endocrinology and metabolism clinics of North…
  • 1 December 1998
The expected therapeutic goals, potential treatment risks, and management of androgen replacement therapy for the adult man are reviewed and the advantages and disadvantages of the various androgen delivery systems currently available and under investigation are discussed. Expand
Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the Massachusetts Male Aging Study.
Elevated levels of TT, total T, bioavailable T, DHEA, and DHEa sulfate are associated with increased physical performance, however, levels beyond those critical concentrations, as might be achieved through exogenous supplementation, do not appear to confer any additional benefit. Expand
Androgen deficiency in the aging male: when, who, and how to investigate and treat.
Urologists should be familiar with ADAM, its clinical manifestations, the rational approach to its diagnosis and treatment, and the consequences of treatment, because prolonged androgen replacement therapy can be associated with significant complications, particularly in the prostrate. Expand
Aging and declining testosterone: past, present, and hopes for the future.
The Brown Norway rat demonstrates age-related reductions in serum T levels in the setting of unchanged or modestly increased serum LH levels, and a discussion of what is known of the molecular mechanisms by which T synthesis declines with Leydig cell aging is discussed. Expand